Cost–effectiveness and budget impact analysis of switching from apixaban to rivaroxaban treatment among patients with nonvalvular atrial fibrillation in a German healthcare setting... by Rupesh Subash, Thomas Strakosch, Michelle Zhang, Melissa Hagan, Elke Dworatzek, Agnes Kisser, Vasileios Vasilopoulos, Chloe Salter, Carissa Dickerso, Ewa Stawowczyk

Epidemiology, disease burden and costs of Duchenne muscular dystrophy in Germany: an observational, retrospective health claims data analysis by Joanna Diesing, Janbernd Kirschner, Astrid Pechmann, Jörg König, Leonie Kunk, Tarcyane Barata Garcia, Carolina Schwedhelm, Carsta Militzer-Horstmann, Ivonne Hänsel, Agnes Kisser

Get full text